Method for Treating Cftr-Mediated Chronic Sinusitis

UA ID Technology #ua18-193

Title: Method for Treating CFTR-Mediated Chronic Sinusitis

Invention: This technology is a drug-based therapeutic for chronic sinusitis (CS) in patients where the disease is caused by a single mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

Background: Chronic sinusitis currently affects nearly 30 million Americans, with treatments including antibiotics and corticosteroids, which are not always effective. When drug therapies are not sufficient at treating CS, surgery can be performed. And while CS is largely caused by environmental factors, it was recently discovered that nearly 10% of CS patients have the disease due to a single mutation in the CFTR gene. The technology presented here looks to help this subpopulation with a more precise treatment that could be more effective than antibiotics or corticosteroids and lessen the amount of surgeries needed.

Applications:
- Treatment of chronic sinusitis

Advantages:
- Treats CS patients with an underlying genetic mutation to CFTR
- Less invasive than surgery
- Increases treatment effectiveness compared to antibiotics and corticosteroids

Licensing Manager:
Rakhi Gibbons
RakhiG@tla.arizona.edu
(520) 626-6695

The University of Arizona, Tucson, Arizona
Inventors

Eugene Chang

Vice Chair, Otolaryngology - Head & Neck Surgery